Updated the following information: • Secondary and exploratory objectives/endpoints including corresponding changes to statistical analysis section • Updated response criteria inclusive of the June 2012 clarification to IWCLL 2008 criteria for assessing response with BCR-inhibiting agents, including guidance to assess the clinical improvement in other disease parameters upon observation of lymphocytosis • Guidelines for concomitant use of CYP inhibiting/inducing drugs, QT prolonging medications, and antiplatelet agents and anticoagulants • Revised Inclusion criteria #5 to include subjects age ≥ 70 years who have received ≥ 2 prior lines of systemic therapy • Clarified that 2 separate randomization schemes were to be generated (one for each geographic region [US versus non-US])

• Provided instructions on administration of ibrutinib in case of planned or unplanned surgery • Allowed allogeneic stem cell transplant within 6 months prior to randomization with no active graft vs. host disease. • Clarified that pre-treatment FISH should be performed on marrow sample for subjects without lymphocytosis (eg, SLL) • Included provisionary language for supplying ibrutinib to control arm subjects • Allowed screening computed tomography (CT) scan from up to 6 weeks prior to randomization

• Allowed subjects treated with ofatumumab and with documented IRC-confirmed progression to receive therapy with ibrutinib at investigator’s discretion • Updated guideline for concomitant use local site or hormonal therapy for non-B cell malignancies and growth factors • Added collection for other malignancies that develop at anytime during study follow-up

• Changed the overall two-sided significance level for PFS from 0.01 to 0.05 following review with global regulatory authorities.